Basic Study
Copyright ©The Author(s) 2022.
World J Gastroenterol. Feb 7, 2022; 28(5): 547-569
Published online Feb 7, 2022. doi: 10.3748/wjg.v28.i5.547
Table 3 Clinicopathological relevance of connective tissue growth factor protein expression in colorectal cancer patients as determined by Western blot analysis
Characteristics
Normal expression (n = 28)
Overexpression (n = 43)
Odds ratio (95%CI)
P value
Chi2
Age
< 506 (28.57)15 (71.43)Referent
≥ 5022 (44.00)28 (56.00)1.9 (0.6-7.1)0.221.47
Gender
Male12 (31.58)26 (68.42)Referent
Female16 (48.48)17 (51.52)2.03 (0.7-6.0)0.152.11
Dwelling
Rural20 (42.55)27 (57.45)Referent
Urban8 (33.33)16 (66.67)0.7 (0.21-2.1)0.450.57
Social class
Low10 (45.45)12 (54.55)Referent
Middle and high18 (36.73)31 (63.27)1.4 (0.5-4.5)0.570.48
Family history
Yes7 (35.00)13 (65.00)Referent
No21 (41.18)30 (58.82)0.7 (0.2-2.5)0.630.23
Smoking status
Yes11 (27.50)29 (72.50)Referent
No17 (54.84)14 (45.16)3.2 (1.1-9.7)0.019a5.46
Lifestyle
Active12 (38.71)19 (61.29)Referent
Sedentary16 (40.00)24 (60.00)1.05 (0.4-0.1)0.910.01
Salt tea intake
Yes25 (38.46)40 (61.54)Referent
No3 (50)3 (50)1.6 (0.2-12.8)0.580.30
Red meat consumption
Yes24 (40.68)35 (59.32)Referent
No4 (33.33)8 (66.67)0.7 (0.1-3.1)0.630.22
Sundried vegetables
Yes19 (39.58)29 (60.42)Referent
No9 (39.13)14 (60.87)1.0 (0.3-3.0)0.970.01
Source of drinking water
Tap water (R)20 (43.48)26 (56.52)Referent
Tap water (L)1 (14.29)6 (85.71)0.21 (0.01-2.3)
Others17 (38.89)11 (61.11)1.3 (0.3-4.6)0.342.21
Pickles
Yes16 (39.02)25 (60.98)Referent
No12 (40)18 (60)1.04 (0.3-3.03)0.930.01
Pesticide exposure
Yes15 (45.45)18 (54.55)Referent
No13 (34.21)25 (65.79)0.624 (0.2-1.8)0.330.93
Junk food consumption
Yes0 (0)5 (100)Referent
No28 (42.42)38 (57.58)0 (0-1.1)0.063.5
Site of tumor
Colon12 (33.33)24 (66.67)Referent
Rectum12 (60)8 (40)3 (0.84-10.89)
Rectosigmoid4 (26.67)11 (73.33)0.7 (0.13-3.1)0.0775.12
Tumor differentiation
Well14 (77.78)4 (22.22)Referent
Moderate13 (28.26)33 (71.74)0.1 (0.02-0.5)
Poor1 (14.29)6 (85.71)0.04 (0.01-0.64)0.000a15.33
Invasion depth
T17 (87.50)1 (12.50)
T213 (59.09)9 (40.91)Referent0.000a18.61
T37 (22.58)24 (77.42)0.04 (0.01-0.44)
T41 (10)9 (90)
T1 + T220 (66.67)10 (33.33)
T3 + T48 (19.51)33 (80.49)0.12 (0.03-0.4)0.000a16.12
TNM staging
I19 (76.00)6 (24.00)Referent
II7 (28.00)18 (72.00)0.12 (0.02-0.5)0.000a23.3
III2 (11.11)16 (88.89)0.04 (0.003-0.3)
IV0 (0.00)3 (100)0 (0-0.5)
I + II26 (52.00)24 (48.00)
III + IV2 (9.52)19 (90.48)0.1 (0.01-0.5)0.001a11.2
Tumor grade
114 (77.78)4 (22.22)Referent
213 (28.26)33 (71.74)0.1 (0.02-0.5)
31 (14.29)6 (85.71)0.05 (0.01-0.6)0.000a15.33
DUKE stage
A4 (80.00)1 (20.00)Referent
B22 (50.00)22 (50.00)4 (0.3-205)
C2 (9.09)20 (90.91)0.02 (0.01-0.5)0.001a13.9
Node status
026 (50.98)25 (49.02)Referent
1 and 22 (7.14)18 (41.86)0.10 (0.01-0.53)0.001a10.10
LVI
Present17 (31.48)37 (68.52)Referent
Absent11 (64.71)6 (35.29)0.2 (0.06-0.90)0.015a5.97
PNI
Present1 (6.67)14 (93.33)Referent
Absent27 (48.21)29 (51.79)0.1 (0.01-0.58)0.003a8.55
TALNR
Present25 (40.32)37 (59.68)Referent
Absent3 (33.33)6 (66.67)0.7 (0.11-3.9)0.6880.16
Necrosis seen
Yes2 (11.11)16 (88.89)Referent
No26 (49.06)27 (50.94)0.2 (0.03-0.76)0.004a8.10
Recurrence
Yes1 (8.33)11 (91.67)Referent
No27 (45.76)32 (54.24)0.3 (0.05-1.34)0.016a5.85
Vital status
Alive27 (40.91)39 (59.09)Referent
Death1 (20.00)4 (80.00)0.4 (0.007-3.9)0.360.85